Fiona H Marshall

List of Publications by Year
in descending order

90 papers	12,507 citations	28274 55 h-index	49909 87 g-index
91 all docs	91 docs citations	91 times ranked	11985 citing authors

#	Article	IF	Citations
1	From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimerâ€™s disease. Cell, 2021, 184, 5886-5901.e22.	28.9	44
2	Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. Journal of Medicinal Chemistry, 2020, 63, 1528-1543.	6.4	46
3	Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure-based drug design. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126611.	2.2	5
4	Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu₅) X-ray Structures. Journal of Medicinal Chemistry, 2019, 62, 207-222.	6.4	67
5	Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals. Scientific Reports, 2018, 8, 41.	3.3	79
6	Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727. Nature, 2018, 553, 111-114.	27.8	110
7	Structurally Enabled Discovery of Adenosine A_{2A} Receptor Antagonists. Chemical Reviews, 2017, 117, 21-37.	47.7	64
8	Structural insight into allosteric modulation of protease-activated receptor 2. Nature, 2017, 545, 112-115.	27.8	192
9	Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. Trends in Pharmacological Sciences, 2017, 38, 837-847.	8.7	106
10	Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature, 2017, 546, 254-258.	27.8	155
11	Structures of Human A 1 and A 2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. Structure, 2017, 25, 1275-1285.e4.	3.3	178
12	Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nature Reviews Drug Discovery, 2017, 16, 787-810.	46.4	125
13	Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures. Current Molecular Pharmacology, 2017, 10, 334-344.	1.5	25
14	Intracellular allosteric antagonism of the CCR9 receptor. Nature, 2016, 540, 462-465.	27.8	192
15	Extra-helical binding site of a glucagon receptor antagonist. Nature, 2016, 533, 274-277.	27.8	190
16	Visualizing GPCR â€˜Megaplexesâ€™ Which Enable Sustained Intracellular Signaling. Trends in Biochemical Sciences, 2016, 41, 985-986.	7.5	9
17	Controlling the Dissociation of Ligands from the Adenosine A_{2A} Receptor through Modulation of Salt Bridge Strength. Journal of Medicinal Chemistry, 2016, 59, 6470-6479.	6.4	151
18	Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors â€“ A Structural Perspective of Ligands and Mutants. Scientific Reports, 2015, 5, 13869.	3.3	38

#	Article	IF	Citations
19	Conformational thermostabilisation of corticotropin releasing factor receptor 1. Scientific Reports, 2015, 5, 11954.	3.3	15
20	Generic GPCR residue numbers â€“ aligning topology maps while minding the gaps. Trends in Pharmacological Sciences, 2015, 36, 22-31.	8.7	387
21	Implications of metabotropic glutamate receptor structures for drug discovery in neurotherapeutics. Expert Review of Neurotherapeutics, 2015, 15, 123-125.	2.8	7
22	From G Protein-coupled Receptor Structure Resolution to Rational Drug Design. Journal of Biological Chemistry, 2015, 290, 19489-19495.	3.4	81
23	Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. MedChemComm, 2015, 6, 947-955.	3.4	15
24	GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1â€“2 September 2014. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 883-903.	3.0	34
25	Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu₅ Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). Journal of Medicinal Chemistry, 2015, 58, 6653-6664.	6.4	150
26	Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discovery Today, 2015, 20, 1355-1364.	6.4	120
27	Purification of Stabilized GPCRs for Structural and Biophysical Analyses. Methods in Molecular Biology, 2015, 1335, 1-15.	0.9	12
28	Structures of mGluRs shed light on the challenges of drug development of allosteric modulators. Current Opinion in Pharmacology, 2015, 20, 1-7.	3.5	29
29	Monoclonal anti-Î²1-adrenergic receptor antibodies activate G protein signaling in the absence of Î²-arrestin recruitment. MAbs, 2014, 6, 246-261.	5.2	31
30	Structure-Based Drug Design for G Protein-Coupled Receptors. Progress in Medicinal Chemistry, 2014, 53, 1-63.	10.4	62
31	Structure of <scp>C</scp>lass <scp>B GPCRs</scp>: new horizons for drug discovery. British Journal of Pharmacology, 2014, 171, 3132-3145.	5.4	96
32	Insights into the structure of class B GPCRs. Trends in Pharmacological Sciences, 2014, 35, 12-22.	8.7	218
33	Binding kinetics differentiates functional antagonism of orexinâ€2 receptor ligands. British Journal of Pharmacology, 2014, 171, 351-363.	5.4	55
34	Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature, 2014, 511, 557-562.	27.8	378
35	Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature, 2013, 499, 438-443.	27.8	378
36	Biophysical Fragment Screening of the Î²₁-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design. Journal of Medicinal Chemistry, 2013, 56, 3446-3455.	6.4	155

#	Article	IF	Citations
37	Preparation of purified GPCRs for structural studies. Biochemical Society Transactions, 2013, 41, 185-190.	3.4	11
38	Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy. Molecular Pharmacology, 2013, 83, 949-958.	2.3	69
39	High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks. In Silico Pharmacology, 2013, 1, .	3.3	72
40	DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Gut chemosensing and the regulation of nutrient absorption and energy supply1. Journal of Animal Science, 2013, 91, 1932-1945.	0.5	32
41	Discovery of 1,2,4-Triazine Derivatives as Adenosine A_{2A} Antagonists using Structure Based Drug Design. Journal of Medicinal Chemistry, 2012, 55, 1898-1903.	6.4	296
42	Identification of Novel Adenosine A_{2A} Receptor Antagonists by Virtual Screening. Journal of Medicinal Chemistry, 2012, 55, 1904-1909.	6.4	131
43	Studies of a ubiquitous receptor family. Nature, 2012, 492, 57-57.	27.8	18
44	New insights from structural biology into the druggability of G protein-coupled receptors. Trends in Pharmacological Sciences, 2012, 33, 249-260.	8.7	158
45	Fragment Screening of GPCRs Using Biophysical Methods: Identification of Ligands of the Adenosine A_{2A} Receptor with Novel Biological Activity. ACS Chemical Biology, 2012, 7, 2064-2073.	3.4	77
46	The Use of GPCR Structures in Drug Design. Advances in Pharmacology, 2011, 62, 1-36.	2.0	38
47	Fragment Screening of Stabilized G-Protein-Coupled Receptors Using Biophysical Methods. Methods in Enzymology, 2011, 493, 115-136.	1.0	103
48	Progress in Structure Based Drug Design for G Protein-Coupled Receptors. Journal of Medicinal Chemistry, 2011, 54, 4283-4311.	6.4	203
49	The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology, 2011, 60, 36-44.	4.1	148
50	Biophysical Mapping of the Adenosine A_{2A} Receptor. Journal of Medicinal Chemistry, 2011, 54, 4312-4323.	6.4	107
51	Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. Structure, 2011, 19, 1283-1293.	3.3	505
52	Biacore analysis with stabilized G-protein-coupled receptors. Analytical Biochemistry, 2011, 409, 267-272.	2.4	66
53	The impact of GPCR structures on pharmacology and structureâ€based drug design. British Journal of Pharmacology, 2010, 159, 986-996.	5.4	123
54	Therapeutic antibodies directed at G protein-coupled receptors. MAbs, 2010, 2, 594-606.	5.2	143

#	Article	IF	Citations
55	Heterodimerization of the GABAB Receptorâ€"Implications for GPCR Signaling and Drug Discovery. Advances in Pharmacology, 2010, 58, 63-91.	2.0	20
56	Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast. Neuropharmacology, 2009, 57, 653-664.	4.1	15
57	The Role of GABAB Receptors in the Regulation of Excitatory Neurotransmission. , 2008, 44, 87-98.		16
58	Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology, 2007, 52, 405-414.	4.1	83
59	Atomoxetine produces changes in cortico-basal thalamic loop circuits: Assessed by phMRI BOLD contrast. Neuropharmacology, 2007, 52, 812-826.	4.1	36
60	Differential effects of the d- and l- isomers of amphetamine on pharmacological MRI BOLD contrast in the rat. Psychopharmacology, 2007, 193, 11-30.	3.1	20
61	Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast. Psychopharmacology, 2006, 189, 369-385.	3.1	36
62	Is the GABA_B Heterodimer a Good Drug Target?. Journal of Molecular Neuroscience, 2005, 26, 169-176.	2.3	33
63	A Summary and Conclusions From the Meeting. Journal of Molecular Neuroscience, 2005, 26, 295-298.	2.3	0
64	GABAB receptor subunits, R1 and R2, in brainstem catecholamine and serotonin neurons. Brain Research, 2003, 970, 35-46.	2.2	32
65	Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid. Journal of Biological Chemistry, 2003, 278, 9869-9874.	3.4	473
66	The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids. Journal of Biological Chemistry, 2003, 278, 11312-11319.	3.4	1,866
67	Heterodimerization of Î³-aminobutyric acid B receptor subunits as revealed by the yeast two-hybrid system. Methods, 2002, 27, 301-310.	3.8	10
68	CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain, 2002, 96, 253-260.	4.2	213
69	International Union of Pharmacology. XXXIII. Mammalian gamma -Aminobutyric AcidB Receptors: Structure and Function. Pharmacological Reviews, 2002, 54, 247-264.	16.0	523
70	Advances in the molecular understanding of GABAB receptors. Trends in Neurosciences, 2001, 24, 277-282.	8.6	90
71	Heterodimerization of G-protein-coupled receptors in the CNS. Current Opinion in Pharmacology, 2001, 1, 40-44.	3.5	45
72	Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells. European Journal of Pharmacology, 2001, 430, 203-210.	3.5	54

#	Article	IF	Citations
73	Protein-Protein Interaction and Not Glycosylation Determines the Binding Selectivity of Heterodimers between the Calcitonin Receptor-like Receptor and the Receptor Activity-modifying Proteins. Journal of Biological Chemistry, 2001, 276, 29575-29581.	3.4	103
74	Characterization of [3 H]-CGP54626A binding to heterodimeric GABAB receptors stably expressed in mammalian cells. British Journal of Pharmacology, 2000, 131, 1766-1774.	5.4	41
75	The GABAB receptor interacts directly with the related transcription factors CREB2 and ATFx. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13967-13972.	7.1	166
76	GABAB receptor heterodimer-component localisation in human brain. Molecular Brain Research, 2000, 77, 111-124.	2.3	67
77	Cellular and sub-cellular localisation of GABAB1 and GABAB2 receptor proteins in the rat cerebellum. Molecular Brain Research, 2000, 83, 72-80.	2.3	67
78	RAMPs: accessory proteins for seven transmembrane domain receptors. Trends in Pharmacological Sciences, 1999, 20, 184-187.	8.7	142
79	GABAB receptors â€“ the first 7TM heterodimers. Trends in Pharmacological Sciences, 1999, 20, 396-399.	8.7	324
80	Calcium sensing properties of the GABAB receptor. Neuropharmacology, 1999, 38, 1647-1656.	4.1	83
81	Heterodimerisation of GABAB receptors. Biochemical Society Transactions, 1999, 27, A70-A70.	3.4	0
82	Heterodimerization is required for the formation of a functional GABAB receptor. Nature, 1998, 396, 679-682.	27.8	1,104
83	Characterization of [³H]â€prostaglandin E₂ binding to prostaglandin EP₄ receptors expressed with Semliki Forest virus. British Journal of Pharmacology, 1997, 121, 1673-1678.	5.4	21
84	Development of Tolerance in Mice to the Sedative Effects of the Neuroactive Steroid Minaxolone Following Chronic Exposure. Pharmacology Biochemistry and Behavior, 1997, 58, 1-8.	2.9	43
85	A Bioluminescent Assay for Agonist Activity at Potentially Any G-Protein-Coupled Receptor. Analytical Biochemistry, 1997, 252, 115-126.	2.4	201
86	G16 as a universal G protein adapter: implications for agonist screening strategies. Trends in Pharmacological Sciences, 1996, 17, 235-237.	8.7	114
87	The pharmacology of GR203040, a novel, potent and selective nonâ€peptide tachykinin NK₁ receptor antagonist. British Journal of Pharmacology, 1995, 116, 3149-3157.	5.4	73
88	Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion. European Journal of Pharmacology, 1995, 294, 163-171.	3.5	9
89	Binding of angiotensin antagonists to rat liver and brain membranes measured ex vivo. British Journal of Pharmacology, 1993, 109, 760-764.	5.4	13
90	Pharmacological profile of GR117289 in vitro: a novel, potent and specific nonâ€peptide angiotensin AT₁ receptor antagonist. British Journal of Pharmacology, 1992, 107, 1173-1180.	5.4	71